Samuel M. Rubinstein, MD, on Relapsed/Refractory Multiple Myeloma: Linvoseltamab Plus Carfilzomib

Posted: Friday, October 31, 2025

Samuel M. Rubinstein, MD, discusses initial results from the carfilzomib cohort of the multicohort LINKER-MM2 trial, which evaluated the combination of the T-cell–redirecting B-cell maturation antigen × CD3 bispecific antibody linvoseltamab and the second-generation proteasome inhibitor in heavily pretreated patients with multiple myeloma (EHA 2025 Abstract S202). 

---